AdipoRon

AdipoRon is a synthetic, orally active small-molecule agonist of adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2). It was discovered by Japanese researchers in 2013 through compound library screening. AdipoRon activates AMPK and PPARα signaling pathways, leading to improved insulin sensitivity, reduced dyslipidemia, and amelioration of glucose intolerance in animal models of type II diabetes and obesity. In preclinical studies, it has also been shown to extend lifespan in obese mice on a high-fat diet and improve exercise endurance. Beyond metabolic effects, AdipoRon demonstrates neuroprotective properties—improving cognitive function and reducing oxidative stress in animal models of neurodegenerative diseases such as Parkinson’s disease. The drug is being investigated for potential therapeutic applications across a range of conditions including obesity, diabetes mellitus type II, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), sarcopenia (age-related muscle loss), mood disorders, anxiety disorders, eating disorders, neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease[2][5][7]. Currently available only for research use; not approved for clinical or therapeutic use[1].